URO-1, Inc. is a life sciences company dedicated to advancing the tools and workflows used in soft tissue biopsy diagnostics.

March 15, 2026 expert reaction to conference abstract comparing prostate cancer and breast cancer screening programmes, being presented at the European Association of Urology Cong ...

The technology is available on the new MyLab™E85 GTS Edition that will be showcased together with the brand new MyLab™C30 GTS ...

The biopsy came back positive. It’s lung cancer.” Countless people in our community hear these words no one ever expects.

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, ...

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

Detailed price information for Medicus Pharma Ltd (MDCX-Q) from The Globe and Mail including charting and trades.

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research.

SkinJect Inc., a wholly owned subsidiary of Medicus Pharma Ltd., is a development-stage life sciences company focused on commercializing a novel, non-invasive treatment for basal cell skin cancer ...